A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects With Chronic HCV Infection
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2016
Price : $35 *
At a glance
- Drugs Sofosbuvir (Primary) ; Velpatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 10 Nov 2015 Results published in the Annals of Internal Medicine
- 14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Nov 2013 Planned number of patients changed from 200 to 300 as reported by ClinicalTrials.gov record.